Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors Abstract #890

Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Aim(s): To retrospectively stage and grade PNET patients and investigate whether the WHO system offers prognostic relevance.
Materials and methods: One-hundred and three patients with PNETs treated since 2004 were included in this study. Mean age at diagnosis was 57. Median duration of follow-up: 50.3 months.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills

To read results and conclusion, please login ...

Further abstracts you may be interested in

#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#378 Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?
Introduction: Small bowel (SB) NETs are regarded as relatively indolent cancers. ENETS has published TNM staging. This study aims to demonstrate whether the TNM stage predicts survival in this cohort of patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Keywords: TNM, survival
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich
#834 Nuclear Imaging in Intermediate Grade Neuroendocrine Tumors
Introduction: Early diagnosis and grading is essential to the treatment decision-making in neuroendocrine tumors. Conventionally, proliferation rate (Ki-67) level is used for the grading of NET. Ga-68 SMS-R PET/CT is the imaging method of choice for the detection of unknown primary neuroendocrine tumors. It is very sensitive in well-differentiated tumors (Ki-67 < 2%). Poorly and undifferentiated tumors having Ki-67 greater than 20% are primarily responsible for false negativity of Ga-68 SMS-R PET/CT. In those patients, FDG-PET is performed to localize the site of the primary tumor.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr. Zeinab A Abou Yehia